BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

At least three new treatments for the inflammatory complications of SARS-CoV-2 infection, each with a target new to clinical COVID-19 countermeasures, have or will soon enter human studies. Movement on other fronts against the pandemic...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | Jul 12, 2019
Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

With new clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's intention to develop multiple sclerosis therapy ibudilast for a differentiated patient population following the approval of two...
BC Week In Review | May 4, 2018
Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from 51 amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase Ib/IIa trial showing that once-daily 60 mg oral ibudilast (Ketas, AV411, MN-166) plus riluzole non-significantly...
BC Week In Review | May 4, 2018
Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that twice-daily oral ibudilast (Ketas, AV411, MN-166) met the secondary endpoint...
BC Week In Review | Mar 30, 2018
Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence. The trial enrolled about...
BC Extra | Mar 29, 2018
Clinical News

MediciNova sinks after meth dependence failure

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) lost $1.74 (15%) to $10.22 on NASDAQ Thursday after reporting that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat...
BC Week In Review | Feb 2, 2018
Clinical News

MediciNova reports additional Phase II data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported data from 51 evaluable amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase II trial showing that once-daily 60 mg oral ibudilast (Ketas, AV411, MN-166) plus riluzole improved...
BC Week In Review | Nov 3, 2017
Clinical News

MediciNova reports Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported top-line data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that up to twice-daily 50 mg oral ibudilast (Ketas, AV411, MN-166)...
BC Week In Review | Aug 8, 2016
Clinical News

Ibudilast: Interim Phase II data

Interim data from 25 evaluable ALS patients without non-invasive ventilator support in a double-blind, U.S. Phase II trial showed that once-daily 60 mg oral MN-166 plus riluzole reduced the mean decline in ALSFRS-R total score...
Items per page:
1 - 10 of 56